The role of low‐dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT)
Authors:
- 1 July 1989
- journal article
- research article
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 96 (7) , 795-802
Abstract
Summary. Between 1964 and 1986, 487 patients with gestational trophoblastic tumour (GTT) were treated with methotrexate and folinic acid. The patients comprise two groups: between 1964 and 1974, 126 patients were treated but were not systematically stratified using a prognostic score before the start of treatment. These patients formed part of the 317 women who were analysed to identify a number of prognostic variables (Bagshawe 1976). Retrospective analysis of these 126 patients using these prognostic factors showed that in the true low‐risk group 85/88 (96%) are alive while 20/22 (91%) of the medium‐risk group and only 5/16 (31%) of the high‐risk group are alive. Overall the survival was 110/126 (87%) with a minimum follow‐up of 14 years. From 1974 all patients were stratified on admission into prognostic groups. Of the true low‐risk patients 347/348 survived (99·7%); 13 patients were underscored and treated as low risk when they should have been treated as medium risk, 12 (92%) of these are alive, but nine (69%) needed to change treatment because of drug resistance. While the overall survival in the 1974–1986 group was 359/361 (99%) with a minimum follow‐up of 16 months, the survival in all patients (1964–1986) was 469/487 (96%). Although the survival in these patients is excellent it should be noted that 69/348 (20%) low‐risk patients had to change treatment because of the development of drug resistance, and a further 23 (6%) needed to change treatment because of drug‐induced toxicity. Low‐dose methotrexate and folinic acid given in the schedule described remains the treatment of choice in patients with low‐risk GTT because of its effectiveness and minimal short‐ and long‐term toxicity. Patients presenting with medium‐ and high‐risk GTT need to start with combination chemotherapy from the outset to avoid the development of drug resistance.Keywords
This publication has 19 references indexed in Scilit:
- Single agent etoposide in gestational trophoblastic tumoursEuropean Journal of Cancer and Clinical Oncology, 1988
- Fertility after chemotherapy for male and female germ cell tumoursInternational Journal of Andrology, 1987
- Fertility in patients with gestational trophoblastic tumors treated with etoposideEuropean Journal of Cancer and Clinical Oncology, 1986
- Developments in chemotherapy for medium‐ and high‐risk patients with gestational trophoblastic tumours (1979–1984)BJOG: An International Journal of Obstetrics & Gynaecology, 1986
- No Increase in Second Tumors after Cytotoxic Chemotherapy for Gestational Trophoblastic TumorsNew England Journal of Medicine, 1983
- Anti-tumour activity of the epipodophyllin derivative VP16–213 (etoposide: NSC-141540) in gestational choriocarcinoma1980
- INFUSION THERAPY FOR PELVIC TROPHOBLASTIC TUMOURSBJOG: An International Journal of Obstetrics & Gynaecology, 1964
- Treatment of Choriocarcinoma with a Combination of Cytotoxic DrugsBMJ, 1960
- INTERFERENCE WITH HORMONAL EFFECTS BY ANTIVITAMINS AND COMPETITION BETWEEN STRUCTURALLY SIMILAR STEROID HORMONESAnnals of the New York Academy of Sciences, 1950
- Inhibition of Estrogen-induced Growth in the Genital Tract of the Female Chick by a Purine Antagonist; Reversal by AdenineScience, 1949